Susquehanna International Group’s Adaptimmune Therapeutics ADAP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-308,065
| Closed | -$40K | – | 12199 |
|
|
2025
Q3 | $40K | Buy |
308,065
+266,280
| +637% | +$36.5K | ﹤0.01% | 11918 |
|
|
2025
Q2 | $10K | Buy |
41,785
+24,441
| +141% | +$6.52K | ﹤0.01% | 12403 |
|
|
2025
Q1 | $3.42K | Sell |
17,344
-11,806
| -41% | -$6.11K | ﹤0.01% | 12278 |
|
|
2024
Q4 | $15.7K | Sell |
29,150
-160,322
| -85% | -$117K | ﹤0.01% | 11944 |
|
|
2024
Q3 | $180K | Sell |
189,472
-52,672
| -22% | -$59.8K | ﹤0.01% | 10568 |
|
|
2024
Q2 | $236K | Buy |
242,144
+185,806
| +330% | +$204K | ﹤0.01% | 9986 |
|
|
2024
Q1 | $89K | Sell |
56,338
-508
| -0.9% | -$613 | ﹤0.01% | 11283 |
|
|
2023
Q4 | $45.1K | Sell |
56,846
-110,042
| -66% | -$62K | ﹤0.01% | 11749 |
|
|
2023
Q3 | $130K | Sell |
166,888
-14,712
| -8% | -$12.3K | ﹤0.01% | 10700 |
|
|
2023
Q2 | $168K | Buy |
+181,600
| New | +$217K | ﹤0.01% | 10453 |
|
|
2023
Q1 | – | Sell |
-28,126
| Closed | -$41.1K | – | 12461 |
|
|
2022
Q4 | $41.1K | Buy |
+28,126
| New | +$45.5K | ﹤0.01% | 11496 |
|
|
2022
Q3 | – | Sell |
-134,912
| Closed | -$229K | – | 13064 |
|
|
2022
Q2 | $229K | Buy |
134,912
+54,805
| +68% | +$94.1K | ﹤0.01% | 10280 |
|
|
2022
Q1 | $165K | Sell |
80,107
-31,981
| -29% | -$86.3K | ﹤0.01% | 11463 |
|
|
2021
Q4 | $420K | Sell |
112,088
-111,326
| -50% | -$507K | ﹤0.01% | 9632 |
|
|
2021
Q3 | $1.16M | Buy |
223,414
+113,204
| +103% | +$508K | ﹤0.01% | 7191 |
|
|
2021
Q2 | $469K | Buy |
110,210
+59,166
| +116% | +$287K | ﹤0.01% | 9739 |
|
|
2021
Q1 | $271K | Sell |
51,044
-96,757
| -65% | -$554K | ﹤0.01% | 10815 |
|
|
2020
Q4 | $796K | Buy |
+147,801
| New | +$803K | ﹤0.01% | 7230 |
|
|
2018
Q4 | – | Sell |
-64,763
| Closed | -$878K | – | 8835 |
|
|
2018
Q3 | $878K | Buy |
+64,763
| New | +$679K | ﹤0.01% | 5477 |
|
|
2018
Q2 | – | Sell |
-54,405
| Closed | -$678K | – | 9512 |
|
|
2018
Q1 | $611K | Buy |
+54,405
| New | +$476K | ﹤0.01% | 6226 |
|
|
2017
Q1 | – | Sell |
-15,941
| Closed | -$65K | – | 8829 |
|
|
2016
Q4 | $65K | Buy |
+15,941
| New | +$76.5K | ﹤0.01% | 9220 |
|
|
2016
Q1 | – | Sell |
-10,844
| Closed | -$131K | – | 8931 |
|
|
2015
Q4 | $131K | Buy |
+10,844
| New | +$106K | ﹤0.01% | 8745 |
|
Other funds holding ADAP
JAIC
EF
RG
XT
Susquehanna International Group's ADAP Position: Q4 2025 in Review
Susquehanna International Group sold out of Adaptimmune Therapeutics (ADAP) in Q4 2025, closing a stake of 308,065 shares — an estimated $40K sold.
Susquehanna International Group first reported a position in ADAP in Q4 2015 and held it in 22 quarters. The position peaked at $1.16M in Q3 2021. 10 funds tracked by Wall St. Rank hold ADAP as of Q4 2025.
- Susquehanna International Group reported no remaining Adaptimmune Therapeutics position as of Q4 2025 after selling out during the quarter.
- Susquehanna International Group sold 308,065 Adaptimmune Therapeutics shares in Q4 2025, an estimated $40K.
- Susquehanna International Group first reported a position in Adaptimmune Therapeutics in Q4 2015 and held it in 22 quarters.
- Susquehanna International Group's Adaptimmune Therapeutics position peaked at $1.16M in Q3 2021.
- 10 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2025.
Based on Susquehanna International Group's 13F filing for Q4 2025, filed 17 Feb 2026.